These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36939068)

  • 41. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative.
    Gwynn RC; Fawzy A; Viho I; Wu Y; Abrams EJ; Nash D
    BMC Health Serv Res; 2015 Jun; 15():247. PubMed ID: 26108273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.
    Ledergerber B; Lundgren JD; Walker AS; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; Gill MJ; Castelli F; Phillips AN;
    Lancet; 2004 Jul 3-9; 364(9428):51-62. PubMed ID: 15234856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users.
    Spillane H; Nicholas S; Tang Z; Szumilin E; Balkan S; Pujades-Rodriguez M
    Trop Med Int Health; 2012 Oct; 17(10):1255-63. PubMed ID: 22863110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Study on the prevalence of loss to follow-up and risk factors among human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients in Baoshan city, Yunnan province].
    Huang D; Zheng W; Yang J; Li Y; Hu A; Xu Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Aug; 48(8):688-92. PubMed ID: 25388464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
    Phillips A; Pezzotti P;
    AIDS; 2004 Jan; 18(1):51-8. PubMed ID: 15090829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poverty stigma is associated with suboptimal HIV care and treatment outcomes among women living with HIV in the United States.
    Leddy AM; Turan JM; Johnson MO; Neilands TB; Kempf MC; Konkle-Parker D; Wingood G; Tien PC; Wilson TE; Logie CH; Weiser SD; Turan B
    AIDS; 2019 Jul; 33(8):1379-1384. PubMed ID: 30870197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cascade of HIV care and population viral suppression in a high-burden region of Kenya.
    Maman D; Zeh C; Mukui I; Kirubi B; Masson S; Opolo V; Szumilin E; Riche B; Etard JF
    AIDS; 2015 Jul; 29(12):1557-65. PubMed ID: 26244395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda.
    Kiwanuka J; Mukulu Waila J; Muhindo Kahungu M; Kitonsa J; Kiwanuka N
    PLoS One; 2020; 15(4):e0217606. PubMed ID: 32255796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mortality among people living with HIV on antiretroviral treatment in Bali, Indonesia: incidence and predictors.
    Utami S; Sawitri AAS; Wulandari LPL; Artawan Eka Putra IWG; Astuti PAS; Wirawan DN; Causer L; Mathers B
    Int J STD AIDS; 2017 Oct; 28(12):1199-1207. PubMed ID: 28201952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and predictors of tuberculosis among HIV-positive adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: a retrospective record review.
    Temesgen B; Kibret GD; Alamirew NM; Melkamu MW; Hibstie YT; Petrucka P; Alebel A
    BMC Public Health; 2019 Nov; 19(1):1566. PubMed ID: 31771552
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mortality and its predictors among antiretroviral therapy naïve HIV-infected individuals with CD4 cell count ≥350 cells/mm(3) compared to the general population: data from a population-based prospective HIV cohort in Uganda.
    Masiira B; Baisley K; Mayanja BN; Kazooba P; Maher D; Kaleebu P
    Glob Health Action; 2014; 7():21843. PubMed ID: 24433941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).
    Jaén A; Esteve A; Miró JM; Tural C; Montoliu A; Ferrer E; Riera M; Segura F; Force L; Sued O; Vilaró J; Garcia I; Masabeu A; Altès J; Coltet B; Podzamczer D; Murillas J; Navarro G; Gatell JM; Casabona J;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):212-20. PubMed ID: 18297762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa.
    Mutevedzi PC; Lessells RJ; Newell ML
    Trop Med Int Health; 2013 Aug; 18(8):934-41. PubMed ID: 23731253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
    May MT; Gompels M; Delpech V; Porter K; Orkin C; Kegg S; Hay P; Johnson M; Palfreeman A; Gilson R; Chadwick D; Martin F; Hill T; Walsh J; Post F; Fisher M; Ainsworth J; Jose S; Leen C; Nelson M; Anderson J; Sabin C;
    AIDS; 2014 May; 28(8):1193-202. PubMed ID: 24556869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment.
    Muiru AN; Madden E; Chilingirian A; Rubinsky AD; Scherzer R; Moore R; Villalobos CPC; Monroy Trujillo JM; Parikh CR; Hsu CY; Shlipak MG; Estrella MM
    HIV Med; 2022 Jul; 23(6):611-619. PubMed ID: 34897925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.